by Clinical Neuropsychologist | Tuesday, December 10, 2024 | Dementia
Abstract INTRODUCTION Recommendations for advance care planning (ACP) in persons with cognitive impairment are based on expert input without insight from actual ACP conversations. METHODS We used thematic analysis to analyze transcripts of ACP conversations for 88...
by Clinical Neuropsychologist | Tuesday, December 10, 2024 | Dementia
Abstract INTRODUCTION The SORL1 locus exhibits protective effects against Alzheimer’s disease (AD) across ancestries, yet systematic studies in diverse populations are sparse. METHODS Logistic regression identified AD-associated SORL1 haplotypes in East Asian...
by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia
Abstract More than 2 million older Americans from underrepresented racial and ethnic minority groups (URGs) have early-stage Alzheimer’s disease and related dementias (ADRD). There are very few scalable recruitment strategies, particularly for Black older...
by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia
Abstract INTRODUCTION Blood-based biomarkers (BBMs) can enable early detection of brain amyloid beta (Aβ) pathology in cognitively unimpaired individuals. However, the extent to which common medical conditions affect biomarker performance remains unclear. METHODS...
by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia
Abstract Recent research highlights the critical role of inflammation in accelerating amyloid beta and phosphorylated tubulin-associated protein tau cascade and Alzheimer’s disease (AD) progression. Emerging evidence suggests that exercise influences AD by...
by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia
Abstract BACKGROUND The diagnostic and prognostic performance of the novel fluid biomarkers brain-derived tau (BD-tau) and phospho-tau217 (p-tau217) in Creutzfeldt–Jakob disease (CJD) is not defined. METHODS We measured cerebrospinal fluid (CSF) and plasma BD-tau,...
